Home > Dermatology > EADV 2019 > Spotlight on Psoriasis > No hint of teratogenicity through ixekizumab

No hint of teratogenicity through ixekizumab

Presented By
Prof. Alexander Egeberg, Herlev and Gentofte Hospital, Denmark
Conference
EADV 2019
Trial
PSOLAR
An analysis of participants from 16 clinical trials who were accidentally exposed to ixekizumab during pregnancy showed no signs of congenital malformations outcomes [1]. In an analysis, presented by Prof. Alexander Egeberg (Herlev and Gentofte Hospital, Denmark), pregnancy outcomes of patients exposed to the interleukin(IL)-17 blocker ixekizumab in clinical trials were assessed and compared with respective US National Vital Statistic System (NVSS; 2017) birth records and data from the multicentre longitudinal, observational registry PSOLAR (Psoriasis Longitudinal Assessment and Registry; June 2007 to August 2012). In total, 2,499 female and 4,517 male patients fathering a pregnancy were exposed to ixekizumab in 16 clinical trials. Data on live births, spontaneous and induced abortions, and congenital malformations were provided for maternal and paternal exposures. Most female patients were exposed to ixekizumab during the first trimester (n=46; 92%...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on